13F Holdings
中文EN

RAJAF TFA Therapeutics, Inc.

Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1885680 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-0.6%
TTM net income YoY31.6%
TTM EPS YoY—
Revenue 3-yr CAGR185.9%
Net income 3-yr CAGR—

Margins

Gross margin61.1%
Operating margin-11.3%
Net margin-12.4%
FCF margin—
EBITDA margin-0.5%

Returns

ROE—
ROA-3.3%
ROIC (approx.)—
Asset turnover0.27x

Leverage & solvency

Liabilities / assets111.5%
Debt / equity—
Current ratio0.19x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.23x
Accruals ratio-2.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$1.25M$1.25M$882,533$53,304$879,318
Cost of revenue$484,607$347,004$116,146$13,746$1.06M
Gross profit$760,741$906,480$766,387$39,558-$176,212
R&D expense———$118,444$25,052
SG&A expense——$538,554$336,235$94,335
Operating income-$141,128-$183,913$227,833-$415,121-$119,387
Interest expense——$26,535$71,772$12,350
Pretax income-$154,822-$191,301$190,815-$415,111-$119,380
Income tax—$34,957$21,530$792$351
Net income-$154,822-$226,258$751,609-$720,093-$491,006
EBITDA-$5,885$223,352$284,590-$390,631$29,851
EPS (basic)0.000.000.01-0.01-4.91
EPS (diluted)0.000.000.01-0.01-4.91
Weighted avg. shares (diluted)111.12M111.12M111.12M104.42M100,000
Banking
Loans, net————$148.90B
Balance sheet
Cash & equivalents$3,199$37,284$23,104$6,628$99,487
Receivables—$305—$149,510$358,006
Inventory$674,196——$313,530$480,352
Current assets$997,742$601,602$327,175$501,552$1.13M
PP&E, net$3.63M$3.91M$2.81M$75,510$1.71M
Total assets$4.66M$4.62M$3.35M$2.10M$3.26M
Current liabilities$5.19M$4.99M$2.97M$2.52M$2.92M
Short-term debt———$57,109—
Long-term debt——$431,079$414,000—
Total debt——$431,079$471,109—
Total liabilities$5.19M$5.00M$3.50M$3.06M$3.54M
Shareholders' equity-$534,551-$375,543-$151,796-$951,334-$275,813
Net debt——$407,975$464,481—
Shares outstanding111.12M111.12M111.12M111.12M111.12M
Cash flow statement
Operating cash flow-$35,845$312,006$359,724-$321,378-$365,363
Capital expenditure—$349,237$319,487$475$100,000
Free cash flow—-$37,231$40,237-$321,853-$465,363
Investing cash flow—-$305,637-$319,820-$475-$110,815
Financing cash flow——-$32,208$245,787$574,504
Depreciation & amortization$135,243$407,265$56,757$24,490$149,238

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.